High intensity focused ultrasound (HIFU) and Eligard in patients with high risk prostate cancer - HELP

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Leuprorelin (Primary)
Indications Prostate cancer
Focus Therapeutic Use
Acronyms HELP

Most Recent Events

21 Mar 2023 Results published in the EDAP media release.
21 Mar 2023 According to EDAP media release, company announced presentation of positive results from this study at the 38th Annual Congress of the European Association of Urology (EAU), which was held from 10th-13th March 2023 in Milan, Italy.
15 Dec 2013 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight